$BIAFJun 2, 2026, 12:02 PMAI processed
bioAffinity to host SAB webinar on real-world use of CyPath Lung noninvasive test
AI Summary
BioAffinity (BIAF, BIAFW) said the Society for Advanced Bronchoscopy will host a webinar on June 16 where a multidisciplinary clinician panel will discuss real-world use of its noninvasive CyPath Lung test to help detect early-stage lung cancer, risk-stratify small nodules, and guide surveillance and treatment decisions. The company highlights CyPath's automated flow cytometry + AI approach and cites a published trial (92% sensitivity, 87% specificity, 99% NPV in high‐risk patients with nodules <20 mm), but provided no new clinical data, sample-size details, or regulatory/reimbursement updates; CyPath is marketed as a Laboratory Developed Test (LDT) and not a sole diagnostic.
Positives
- Multidisciplinary clinician panel webinar (June 16) signals growing clinical engagement with CyPath
- Published trial metrics cited: 92% sensitivity, 87% specificity, 99% NPV in high‑risk patients with nodules <20 mm
- High NPV could help spare patients from unnecessary invasive procedures and influence management of small nodules
Negatives
- CyPath is marketed as an LDT and is not intended as a sole diagnostic, limiting regulatory standing
- Announcement contains no new clinical data, prospective validation details, or regulatory/reimbursement updates
- Press release does not disclose trial sample size or independent validation details